Innate Pharma Target Price

Innate Pharma posts a target price of $6.7. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $6.7 for IPHA means covering analysts, on average, see the stock 207.2% upside of $2.17 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for IPHA's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Innate Pharma's other metric pages and overview cover the third.

Judging Innate Pharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $6.7 here, then scan peer and history charts to see if the gap is persistent.